P.04.16 CHROMOGRANIN A AS A MARKER IN THE FOLLOW UP OF GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NENS). A SYSTEMATIC REVIEW

2018 ◽  
Vol 50 (2) ◽  
pp. 162
Author(s):  
R.E. Rossi ◽  
C. Ciafardini ◽  
D. Conte ◽  
V. Sciola ◽  
S. Massironi
Keyword(s):  
Systematic Review ◽  
Chromogranin A ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms

Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms

Surgery ◽  
2019 ◽  
Vol 165 (4) ◽  
pp. 672-685 ◽  
Author(s):  
Roxanne Y.A. Teo ◽  
Timothy Z. Teo ◽  
David W.M. Tai ◽  
Damien M. Tan ◽  
Simon Ong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms

scholarly journals Short- and long-term outcomes of laparoscopic organ-sparing resection for pancreatic neuroendocrine neoplasms

2020 ◽  
Author(s):  
Ren-Chao Zhang ◽  
Jun Ma ◽  
yiping mou ◽  
Yu-Cheng Zhou ◽  
Wei-Wei Jin ◽  
...  
Keyword(s):  
Distal Pancreatectomy ◽  
Neuroendocrine Neoplasms ◽  
Transfusion Rate ◽  
Long Term Outcomes ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Spleen Preserving ◽  
Short And Long Term ◽  
Organ Sparing

Abstract Background：Pancreatic neuroendocrine neoplasms (PNENs) are rare neoplasms associated with a long life expectancy after resection. In this setting, patients may benefit from laparoscopic organ-sparing resection. Studies of laparoscopic organ-sparing resection for PNENs are limited. The aim of this study was to evaluate the short- and long-term outcomes of laparoscopic organ-sparing resection for PNENs.Methods： A retrospective study was performed for patients with PNENs who underwent laparoscopic organ-sparing pancreatectomy between March 2005 and May 2018. The patients’ demographic data, operative results, pathological reports, hospital courses and morbidity, mortality, and follow-up data (until August 2018) were analysed.Results：Thirty-five patients were included in the final analysis. There were 9 male and 26 female patients, with a median age of 46 years (range, 25-75 years). The mean BMI was 24.6±3.3 kg/m2. Nine patients received laparoscopic enucleation (LE), 20 received laparoscopic spleen-preserving distal pancreatectomy (LSPDP), and 6 received laparoscopic central pancreatectomy. The operative time, intraoperative blood loss, transfusion rate, and postoperative hospital stay were 186.4±60.2 min, 165±73.0 ml, 0 d, and 9 d (range, 5-23 d), respectively. The morbidity rate, grade ≥III complication rate and grade ≥B pancreatic fistula rate were 34.2%, 11.4%, and 8.7%, respectively, with no mortality. The rate of follow-up was 94.3%, and the median follow-up time was 55 months (range, 3-158 months). One patient developed recurrence 36 months after LE and was managed with surgical resection. The other patients survived without metastases or recurrence during the follow-up. One patient had diabetes after laparoscopic spleen-preserving distal pancreatectomy, and no patients had symptoms of pancreatic exocrine insufficiency. Conclusions： Laparoscopic organ-sparing resection for selected cases of PNENs is safe and feasible and has favourable short- and long-term outcomes.

VHL-RELATED NEUROENDOCRINE NEOPLASMS AND BEYOND: AN ISRAELI SPECIALIZED CENTER REAL-LIFE REPORT

2020 ◽  
Vol 26 (10) ◽  
pp. 1131-1142
Author(s):  
Auryan Szalat ◽  
Kira Oleinikov ◽  
Avital Nahmias ◽  
Vardiella Meiner ◽  
Simona Ben-Haim ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Neuroendocrine Tumor ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Von Hippel Lindau ◽  
Mutation Carriers ◽  
Long Term Follow Up

Objective: Von Hippel-Lindau (VHL) syndrome is a rare and complex disease. In 1996, we described a 3 generation VHL 2A kindred with 11 mutation carriers. We aim to share our experience regarding the long-term follow-up of this family and the management of all our other VHL patients focusing on frequently encountered neuroendocrine neoplasms: pheochromocytoma/paraganglioma and pancreatic neuroendocrine neoplasms (PNEN). Methods: All VHL patients in follow-up at our tertiary center from 1980 to 2019 were identified. Clinical, laboratory, imaging, and therapeutic characteristics were retrospectively analyzed. Results: We identified 32 VHL patients in 16 different families, 7/16 were classified as VHL 2 subtype. In the previously described family, the 4 initially asymptomatic carriers developed a neuroendocrine tumor; 7 new children were born, 3 of them being mutation carriers; 2 patients died, 1 due to metastatic PNEN-related liver failure. Pheochromocytoma was frequent (22/32), bilateral (13/22;59%), often diagnosed in early childhood when active screening was timely performed, associated with paraganglioma in 5/22, rarely malignant (1/22), and recurred after surgery in some cases after more than 20 years. PNEN occurred in 8/32 patients (25%), and was metastatic in 3 patients. Surgery and palliative therapy allowed relatively satisfactory outcomes. Severe disabling morbidities due to central-nervous system and ophthalmologic hemangiomas, and other rare tumors as chondrosarcoma in 2 patients and polycythemia in 1 patient were observed. Conclusion: A multidisciplinary approach and long-term follow-up is mandatory in VHL patients to manage the multiple debilitating morbidities and delay mortality in these complex patients. Abbreviations: CNS = central nervous system; HIF = hypoxia inducible factor; PGL = paraganglioma; PHD = prolyl hydroxylase; Pheo = pheochromocytoma; PNEN = pancreatic neuroendocrine neoplasms; PNET = pancreatic neuroendocrine tumor; RCC = clear cell renal cell carcinoma; VHL = Von Hippel-Lindau

Adrenocorticotropic Hormone-Producing Pancreatic Neuroendocrine Neoplasms: A Systematic Review

2021 ◽  
Vol 27 (2) ◽  
pp. 152-157
Author(s):  
Yi Wu ◽  
Guangbing Xiong ◽  
Hang Zhang ◽  
Min Wang ◽  
Feng Zhu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Adrenocorticotropic Hormone ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms

Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review

2016 ◽  
Vol 61 (1) ◽  
pp. 147-153 ◽  
Author(s):  
Raffaele Pezzilli ◽  
Stefano Partelli ◽  
Renato Cannizzaro ◽  
Nico Pagano ◽  
Stefano Crippa ◽  
...  
Keyword(s):  
Systematic Review ◽  
Neuroendocrine Neoplasms ◽  
Therapeutic Decision ◽  
Ki 67 ◽  
Pancreatic Neuroendocrine Neoplasms
Sign in / Sign up

Export Citation Format

Share Document